RxDoctor Payments Data

Robert Kohn, MD

Geriatric Psychiatry · Providence, RINPI 1629082458

Payments from drug & device makers

$3,707in general payments, 2019–2025

Across 153 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$934
  • Johnson & Johnson$635
  • Vanda Pharmaceuticals Inc.$389
  • Otsuka America Pharmaceutical, Inc.$362
  • AbbVie$317
  • Lundbeck LLC$305
  • plus $765 from 9 others

What the payments were for

  • Consulting fees$2005%
  • Food & beverage$3,10784%
  • Education$40011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few geriatric psychiatry providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$382,263
Medicare patients
196
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl523$640,362
AustedoDeutetrabenazine49$538,479
Austedo XrDeutetrabenazine72$511,518
IngrezzaValbenazine Tosylate34$284,427
VraylarCariprazine Hcl44$57,189
RexultiBrexpiprazole40$55,287
AristadaAripiprazole Lauroxil12$38,627
Aripiprazole571$28,858
Quetiapine Fumarate ErQuetiapine Fumarate338$22,226
LatudaLurasidone Hcl11$16,886
Bupropion XlBupropion Hcl793$16,791
TrintellixVortioxetine Hydrobromide17$15,082
Clonazepam1,215$14,050
Venlafaxine Hcl ErVenlafaxine Hcl727$14,031
Sertraline Hcl748$13,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$934$1,049,997121 claims
Johnson & JohnsonSpravato$635$640,362523 claims
Neurocrine Biosciences, Inc.Ingrezza$226$284,42734 claims
AbbVieVraylar$317$57,18944 claims
Otsuka America Pharmaceutical, Inc.Rexulti$362$55,28740 claims
Alkermes, Inc.Aristada$26$38,62712 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$55$19,45628 claims
MerckBelsomra$75$11,82727 claims
Lilly USA, LLCOlanzapine$21$5,128231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric psychiatry providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.

Other geriatric psychiatry in Providence

Where these figures come from

Is this you, or does something look wrong? →